Cargando…

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China

Objective. This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China. Methods. A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, J., Liu, L. Y., Wu, P. H., Liao, Y., Tao, T., Liu, W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960773/ https://www.ncbi.nlm.nih.gov/pubmed/24772445 http://dx.doi.org/10.1155/2014/294017

Ejemplares similares

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Moses, Robert
Publicado: (2009)

Comparison of Glycemic Excursion in Patients with New Onset Type 2 Diabetes Mellitus before and after Treatment with Repaglinide
por: Hezarkhani, Sharabeh, et al.
Publicado: (2013)

Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2014)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
por: Xie, Jing, et al.
Publicado: (2019)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus
por: Li, Qingchu, et al.
Publicado: (2017)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes
por: Richard, John W., et al.
Publicado: (2011)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses, Robert G
Publicado: (2010)

Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats
por: Chukwunonso Obi, Bonaventure, et al.
Publicado: (2016)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Could Metformin Manage Gestational Diabetes Mellitus instead of Insulin?
por: Saleh, Hend S., et al.
Publicado: (2016)

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
por: Li, Tian, et al.
Publicado: (2021)

A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients
por: Zhou, Xueyan, et al.
Publicado: (2019)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

Meglitinide (repaglinide) therapy in permanent neonatal diabetes mellitus: two case reports
por: Razzaghy-Azar, Maryam, et al.
Publicado: (2021)

Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin
por: Huang, Tao, et al.
Publicado: (2018)

Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Zhang, Rong, et al.
Publicado: (2017)

MTNR1B Gene Polymorphisms Are Associated With the Therapeutic Responses to Repaglinide in Chinese Patients With Type 2 Diabetes Mellitus
por: Wang, Tao, et al.
Publicado: (2019)

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea
por: Omori, Kazuno, et al.
Publicado: (2018)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus
por: Wang, Liang-Chen, et al.
Publicado: (2018)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Severe Thrombocytopenia Due to Repaglinide in a Patient With Type 2 Diabetes
por: Katsuyama, Hisayuki, et al.
Publicado: (2013)

A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients
por: Zhou, Xueyan, et al.
Publicado: (2016)

Effects of Metformin on the Cerebral Metabolic Changes in Type 2 Diabetic Patients
por: Huang, Yung-Cheng, et al.
Publicado: (2014)

Association of the HLA-DQA1 and HLA-DQB1 Alleles in Type 2 Diabetes Mellitus and Diabetic Nephropathy in the Han Ethnicity of China
por: Ma, Ze-Jun, et al.
Publicado: (2013)

Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study
por: Du, Guoli, et al.
Publicado: (2020)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Repaglinide-Induced Acute Pancreatitis
por: Udongwo, Ndausung, et al.
Publicado: (2021)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Factors Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus
por: He, Bin-Bin, et al.
Publicado: (2012)

Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin
por: Kawamori, Ryuzo, et al.
Publicado: (2015)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer
por: Garrett, C R, et al.
Publicado: (2012)

Enhanced Apoptosis of Monocytes from Complication-Free Juvenile-Onset Diabetes Mellitus Type 1 May Be Ameliorated by TNF-α Inhibitors
por: Myśliwska, Jolanta, et al.
Publicado: (2014)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_55khgogh1971ol12v5stus6dl5